Opthea Limited (ASX:OPT) Completes Final Patient Visit in Phase 3 COAST Trial
Clinical Trial Completion
Opthea Limited has completed the final week 52 patient visit in the COAST Phase 3 trial, the first of two pivotal studies evaluating the safety and superiority of sozinibercept combined with aflibercept for treating wet AMD.
Future Outlook
The company anticipates announcing topline results for the COAST trial in early Q2 CY25, with results from the ShORe trial expected mid-CY25.
Executive Comments
Frederic Guerard, PharmD, Chief Executive Officer of Opthea, stated, “The completion of the final week 52 patient visit in COAST is an important milestone in the development of sozinibercept, as we deliver on our mission of improving visual outcomes in patients with wet AMD to enable fuller and healthier lives. I would like to thank Charles Wykoff, MD, PhD as well as all of the COAST investigators and their clinical staff for their excellent work as we plan to announce the anticipated topline data in early Q2 CY25.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.